Skip to content
Peptigraph home

Cagrilintide Dosage: Doses Studied, Units and Chart

What doses of Cagrilintide have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureAmylin analogUpdated
Doses studied
6 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
159-195 h (with semaglutide 2.4 mg co-administered)
subcutaneous, in people · Lancet 2021, PMID 33894838
Vial sizes sold
2.5 mg, 5 mg, 10 mg

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of Cagrilintide used in published studies
DoseFrequency and routeStudy typeSource
0.6 mg (renal study) or 0.9 mg (hepatic study), single dosesingle dose · subcutaneous · single doseHuman controlled trialClinical pharmacokinetics 2026, PMID 42228334
dose escalated to 4.5 mg (placebo arm received single oral moxifloxacin 400 mg as positive control)once weekly · subcutaneousHuman RCTn = 105Diabetes, obesity & metabolism 2024, PMID 39279639
2.4 mg (cagrilintide arm)once weekly · subcutaneous · 32 weeksHuman RCTn = 92Lancet 2023, PMID 37364590
0.3, 0.6, 1.2, 2.4 or 4.5 mg (vs liraglutide 3.0 mg daily or placebo)once weekly · subcutaneous · 26 weeks plus 6 weeks follow-upHuman RCTLancet 2021, PMID 34798060
cagrilintide 0.16-4.5 mg plus semaglutide 2.4 mg, vs placebo plus semaglutideonce weekly · subcutaneous · 20 weeks (16 weeks co-escalation, 4 weeks at target dose)Human RCTn = 96Lancet 2021, PMID 33894838
3 nmol/kgonce daily · subcutaneous · 3 weeksAnimal · mouse (not a human result)EBioMedicine 2025, PMID 40609154

Dose to syringe units

For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.

0.25 mg
5 u
0.5 mg
10 u
1 mg
20 u
1.5 mg
30 u
2 mg
40 u
2.5 mg
50 u
Use your own vial and water

Before anyone considers it

  • Cagrilintide is investigational and not approved for any use.
  • Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

How the phase 2 trial built its dose arms

The phase 2 weight trial tested once-weekly cagrilintide at 0.3, 0.6, 1.2, 2.4 and 4.5 mg against once-daily liraglutide 3.0 mg or placebo.[5]

Treatment lasted 26 weeks, including a dose-escalation period of up to 6 weeks and a follow-up of 6 weeks with no treatment.[5]

When it was dosed with semaglutide

In the phase 1b trial the cagrilintide and semaglutide doses were co-escalated in 4-week intervals over 16 weeks and held at target for 4 weeks.[6]

Cagrilintide amounts there ran from 0.16 to 4.5 mg alongside semaglutide 2.4 mg.[6]

The phase 3a trial in adults without diabetes lasted 68 weeks and compared cagrilintide 2.4 mg plus semaglutide 2.4 mg with each drug alone at 2.4 mg and with placebo.[9]

The companion phase 3a trial in people with type 2 diabetes gave 2.4 mg of each drug once a week, or placebo, for 68 weeks, with no cagrilintide-alone arm.[10]

Single doses in impaired organs

In studies grouped by renal or hepatic function, participants received a single cagrilintide dose of 0.6 or 0.9 mg respectively.[3]

Studied cagrilintide doses in syringe units (10 mg vial)

With a 10 mg vial mixed in 2 mL (5 mg/mL) and read on a U-100 syringe, the phase 2 weekly doses come to: 0.3 mg = 6 units, 0.6 mg = 12 units, 1.2 mg = 24 units, 2.4 mg = 48 units, 4.5 mg = 90 units.

Calculated from vial mg 10; water mL 2; mg per mL 5; u100 units per mL 100; dose source phase 2 arms, PMID 34798060 (0.3, 0.6, 1.2, 2.4, 4.5 mg); doses mg 0.3, 0.6, 1.2, 2.4, 4.5. Formula: units = doseMg / mgPerMl x 100

With the same vial mixed in 1 mL (10 mg/mL) the doses read: 0.3 mg = 3 units, 0.6 mg = 6 units, 1.2 mg = 12 units, 2.4 mg = 24 units, 4.5 mg = 45 units. The 0.3 mg dose is below 5 units, which is hard to measure accurately.

Calculated from vial mg 10; water mL 1; mg per mL 10; u100 units per mL 100; doses mg 0.3, 0.6, 1.2, 2.4, 4.5. Formula: units = doseMg / mgPerMl x 100; flag units < 5

Common questions

How many units is 1 mg of Cagrilintide?

It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 1 mg is 20 units on a U-100 syringe. Use the calculator for other mixes.

Is Cagrilintide FDA approved?

No. Cagrilintide is investigational (investigational (cagrisema component)) and not approved for any use.

What is the cagrilintide starting dose?

No single starting dose is stated; the phase 2 abstract describes dose escalation of up to 6 weeks toward the assigned weekly amount.[5]

Is there a cagrilintide dosage chart?

Drugs@FDA lists no cagrilintide product, so there is no labelled chart; the phase 2 arms are the only dose table in this file.[11]

Has cagrilintide been studied with tirzepatide?

We found no trial that gave cagrilintide together with tirzepatide; the co-administration trials found for cagrilintide all used semaglutide.

Calculated from pubmed query (cagrilintide[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); records matched 32; studied no; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json (cagrilintide__tirzepatide); studies listed = 0

How was cagrilintide titrated in trials?

The registry record for the phase 3 cagrilintide-semaglutide trial describes a 16-week dose-escalation period followed by 52 weeks of maintenance. It does not list the individual step doses.[12]

More on Cagrilintide

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  4. 4Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  5. 5Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  6. 6Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  7. 7Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025PMID 40609154Accessed 2 Oct 2026
  8. 8Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
  9. 9Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
  10. 10Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
  11. 11Drugs@FDA (openFDA) search: active ingredient "cagrilintide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  12. 12Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.